As part of the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) program, the efficacy of once-weekly subcutaneous semaglutide was evaluated in over 7,000 patients in six global phase IIIa trials (SUSTAIN 16) across the wide spectrum of the T2D disease course ( Table 1 )
And for that reason, we have the semaglutide that can really help the GLP 1 in higher amounts, which is the semaglutide, the injection we're giving
The theoretical argument is that it might reduce the acute receptor burden that triggers GI side effects, since each injection delivers less peptide
Set Realistic Goals: Celebrate small victories, whether its shedding a few pounds, managing your glucose levels, or feeling more energized
Disclaimer Statements regarding this product are provided for informational and research reference only